HOME >> BIOLOGY >> NEWS
Next-era targeted therapy overcoming Gleevec's shortcomings

Anaheim, Calif. -- Though Gleevec has shown "wonder drug" capabilities for treating chronic myelogenous leukemia and other cancers, experience in treating patients has revealed some shortcomings. In some cases, patients have undergone relapse after building a resistance to the drug. For others with advanced disease, the drug has failed to produce durable remissions.

However, a molecular understanding of resistance has rapidly led to a new generation of drugs that might prove more effective than Gleevec.

Two studies presented here at the 96th Annual Meeting of the American Association for Cancer Research report that a new compound, known as AMN107, may one day offer a more potent alternative for treating patients with acquired Gleevec resistance and others with advanced CML.

As originally conceived, Gleevec works in CML patients by selectively deactivating Bcr-Abl, the abnormal tyrosine kinase protein that triggers rapid growth of leukemic cells. Gleevec was hailed as the first approved drug to directly inhibit the activity of an enzyme known to cause uncontrolled cell growth, and it has been highly successful for many patients.

Scientists soon recognized, however, that some patients develop mutations in the Bcr-Abl protein that drastically reduce Gleevec's effectiveness.

AMN107 Holds Promise for Treating Gleevec-Resistant Leukemia According to Oregon Scientists: Abstract 5282

To overcome resistance to Gleevec, scientists are designing new compounds that bind tighter to the intended target, the Bcr-Abl protein. One such candidate drug is AMN107, synthesized by Novartis Pharmaceuticals in Basel, Switzerland, and characterized in collaboration with investigators at the Dana Farber Cancer Institute.

In essence, AMN107 retains half the chemical makeup of Gleevec, while the other half was engineered to assure a tighter link to Bcr-Abl, thus increasing potency and potentially overcoming resistance due to mutations
'"/>

Contact: Warren R. Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
19-Apr-2005


Page: 1 2 3 4

Related biology news :

1. Genomic signatures identify targeted therapies for lung cancer
2. Nanocomposite labeled cancer cells can be targeted and destroyed using lasers
3. Progress toward a targeted therapy for a specific form of leukemia
4. NDDO and ESMO joined by US National Cancer Institute in conferences on targeted cancer therapies
5. Biomarkers of response to VEGF pathway-targeted therapy discovered for renal cell carcinoma
6. Light activated anticancer drug targeted to DNA using cisplatin like sub-units
7. Researcher looks for more targeted way to deliver cancer drugs
8. UCLA scientists find male gene in brain area targeted by Parkinsons
9. New targeted treatment for brain tumors shows promise in pre-clinical models
10. UCLA scientists uncover mechanism of response to targeted therapy
11. Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments ... consulting, Nanoscience Analytical offers a broad range of contract analysis services for ...
Breaking Biology Technology:
Cached News: